COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety & Accuracy Study of the ActiSight Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00819533
Recruitment Status : Completed
First Posted : January 9, 2009
Last Update Posted : December 29, 2009
Information provided by:
ActiViews Ltd.

Brief Summary:
This study is designed to evaluate preliminary safety and accuracy of the ActiSight™ Needle Guidance System in patients undergoing CT-guided lung aspiration or biopsy. This image guidance system uses a combination of CT scans and camera images to help guide a biopsy needle to a lung lesion. The system displays a simulated image of a biopsy needle and its estimated path for the biopsy.

Condition or disease Intervention/treatment Phase
Biopsy Device: sensor (ActiSight™ Needle Guidance System) Not Applicable

Detailed Description:

Why is this study conducted to demonstrate the safety and effectiveness of the ActiSight Needle Guidance System in assisting trained physicians perform CT guided percutaneous needle biopsy (PNB) and fine needle aspiration (FNA) procedures in the chest.

Subjects, who are scheduled for medically indicated chest PNB or FNA procedures and meet all the inclusion and exclusion criteria, will be asked to participate in the study. The aim is to enroll 40 subjects that will complete the whole study.

Recruited subjects will go through screening tests and if eligible, will undergo, within 18 days of screening, CT Guided chest PNB or FNA utilizing the ActiSight Needle Guidance system. Subjects will be observed and tested for at least an hour after the procedure to detect any serious complications. A follow-up will be conducted within 7-10 days after the procedure day for safety evaluations. Safety and accuracy data from all stages of the study will be collected and analyzed.

The effectiveness of the guidance system will be measured primarily by the frequency of reaching the intended targets, as determined by a final CT scan. Other measures will include the number of needle punctures and the number of intermediate CT scans needed to complete the procedure. The safety of the system will be measured by the frequency and severity of adverse events.

Procedure description:

First, a single-use, disposable pad (ActiSticker) is attached to the patient's skin over the point of needle insertion as selected by the interventionist. The pad incorporates reference objects that are easily detectable both on CT images and visually. A volume CT scan, covering at least the pad, the target lesion and adjacent structures is then performed. Next, the CT images from the volume scan are transferred to the ActiSight computer where the operator marks the target of the procedure, as well as all the reference points on the ActiSticker. Next, an optical sensor, also single-use and disposable, is attached to the top of the needle. By optically detecting all the reference points and relating them to their known positions on the CT images, the system can calculate the position of the top and the tip of the needle with relation to the target lesion. During the procedure, the system shows the user, on a graphic computer display, whether the needle is aimed directly at the target and how far the tip of the needle is from the intended target to help the user aim the insertion and guidance of the needle to the target.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Prospective, Open-Label, Single-Arm, Single-Center Study Evaluating the Preliminary Safety and Accuracy of the ActiSight Needle Guidance System in Patients Undergoing CT-Guided Percutaneous Chest Aspiration and Biopsy
Study Start Date : January 2008
Actual Primary Completion Date : October 2009
Actual Study Completion Date : October 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Biopsy

Arm Intervention/treatment
Experimental: sensor
Patients will have their lung sample obtained under CT and ActiSight needle guidance system
Device: sensor (ActiSight™ Needle Guidance System)
Patients will have their lung sample obtained under CT and ActiSight needle guidance system

Primary Outcome Measures :
  1. Frequency of target reached within a radius of 5 mm from the preplanned targeted point as measured on the final CT scan [ Time Frame: Measure evaluated during entire course of study ]

Secondary Outcome Measures :
  1. Number of punctures required to obtain sample [ Time Frame: Measure evaluated during entire course of study ]
  2. Number of intermediate CT scans required to obtain sample [ Time Frame: During entire course of study ]
  3. An adequate sample obtained during the procedure [ Time Frame: during entire course of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female subjects, 18 years of age or older at the time of enrollment
  • Subjects meeting all medical conditions for percutaneous chest aspiration/biopsy with safe path to lesion between ribs, however, not in the breast area in women or men with gynecomastia
  • Single target pulmonary lesion greater than 10 mm in size (diameter) and depth of lesion greater than 40 mm from the skin
  • Written informed consent to participate in the study
  • Ability to comply with the requirements of the study procedures

Exclusion Criteria:

  • Fibrous tissue or cyst in access path (not including target lesion)
  • Hemophilia, thrombocytopenia, coagulopathy, or other elevated risk for bleeding or abnormal clotting
  • Use of ticlodipine or similar antithrombotic medication
  • For subjects taking warfarin or other anticoagulant medication, INR >1.3
  • Pulmonary hypertension, heart failure, renal failure, or blood dyscrasia
  • Patient is unable to comply with requirements of the procedure, i.e. holding breath
  • Participation in any prior investigational trial within 30 days of enrollment
  • Any form of substance abuse (including drug or alcohol abuse), psychiatric disorder, or any chronic condition that could, in the opinion of the investigator, of interfering with the conduct of the study.
  • Subjects who are uncooperative or cannot follow instructions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00819533

Layout table for location information
Canada, Ontario
University Health Network, Toronto General Hospital
Toronto, Ontario, Canada
Sponsors and Collaborators
ActiViews Ltd.
Layout table for investigator information
Principal Investigator: Narinder Paul, MD University Health Network, Toronto General Hospital
Study Director: Uri Shreter, Ph.D. ActiViews Ltd.
Layout table for additonal information
Responsible Party: Uri Shreter, PhD / Study Director, ActiViews Identifier: NCT00819533    
Other Study ID Numbers: ASNG-LFNA-101-CAN
First Posted: January 9, 2009    Key Record Dates
Last Update Posted: December 29, 2009
Last Verified: December 2009